Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases are potential molecular targets for obtaining both anti-tumor cell progression and anti-angiogenesis effects in cancers, including hepatocellular carcinoma (HCC). Sorafenib is an oral multi-kinase inhibitor that mainly targets Raf kinases and receptor tyrosine kinases associated with angiogenesis (VEGFR-2/-3, PDGFR-beta). A global randomized controlled trial (RCT) of sorafenib versus placebo conducted in patients with advanced HCC demonstrated the beneficial effects of the drug on the time-to-progression and overall survival. Furthermore, a RCT with a similar design to that of the global trial conducted in the Asia-Pacific region also demonstrated the efficacy of the drug. The most common treatment-related adverse events of sorafenib were found to be diarrhea, fatigue, and skin toxicity, namely, hand-foot syndromes and rash. Based on the results of the RCTs, sorafenib has been established as a standard agent for systemic chemotherapy in HCC patients with metastatic disease or transcatheter arterial chemoembolization (TACE)-refractory disease who are not suitable candidates for local treatments. The efficacy and safety of sorafenib in patients with moderate liver dysfunction have not been confirmed to date and more data are needed. Development of new therapeutic methods is needed for the treatment of advanced HCC in the future; clinical trials of sorafenib-based combination therapy, second-line therapy after sorafenib failure, and adjuvant therapy after local treatments are warranted in HCC patients.
Furuse
Junji
J
Department of Internal Medicine, Medical Oncology, School of Medicine, Kyorin University.
Ann Surg Oncol. 2003 May;10(4):355-62
12734082
Cancer Res. 2003 Apr 1;63(7):1454-7
12670889
N Engl J Med. 1999 Mar 11;340(10):745-50
10072408
J Clin Oncol. 2008 Jun 20;26(18):2992-8
18565886
Nature. 2002 Jun 27;417(6892):949-54
12068308
Oncogene. 2001 May 3;20(20):2606-10
11420671
Br J Surg. 1973 Aug;60(8):646-9
4541913
Hepatol Res. 2004 Jun;29(2):113-121
15163433
Semin Oncol. 2006 Aug;33(4):392-406
16890795
Clin Cancer Res. 1999 Jul;5(7):1676-81
10430068
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8
16234567
J Virol. 2007 Jun;81(12):6757-60
17428866
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
17016424
Hepatology. 1998 Apr;27(4):951-8
9537433
Cancer Sci. 2008 Jan;99(1):159-65
17953709
Hepatol Res. 2005 Jul;32(3):163-72
16024288
Oncology. 2007;72 Suppl 1:2-15
18087177
Curr Opin Cell Biol. 1999 Apr;11(2):184-9
10209149
Int J Cancer. 2001 Oct 15;94(2):290-6
11668511
Cancer. 2005 Feb 15;103(4):756-62
15637692
Oncogene. 2006 Jun 26;25(27):3866-84
16799628
Oncology. 1992;49(2):139-42
1315428
Cancer Res. 2006 Dec 15;66(24):11851-8
17178882
J Hepatol. 1997 Nov;27(5):854-61
9382973
Am J Hum Genet. 2008 Mar;82(3):631-40
18313023
Hepatology. 1998 Jul;28(1):68-77
9657098
Nat Genet. 2007 Oct;39(10):1217-24
17873874
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Cancer Res. 1995 Sep 15;55(18):4182-7
7664295
Pharmacol Ther. 1999 May-Jun;82(2-3):241-50
10454201
J Clin Oncol. 2006 Sep 10;24(26):4293-300
16908937
BMC Gastroenterol. 2003 Aug 08;3:19
12906713
Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74
17160391
J Clin Oncol. 2003 Feb 1;21(3):421-7
12560429
Hepatology. 2005 Nov;42(5):1208-36
16250051
J Clin Oncol. 2005 Feb 10;23(5):965-72
15613696
Science. 2002 Jun 28;296(5577):2404-7
12089446
J Hepatol. 2001 Sep;35(3):421-30
11592607
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
Cancer. 1988 Aug 1;62(3):479-83
2839280
Br J Surg. 2004 Oct;91(10):1354-60
15376182
Biochem Biophys Res Commun. 1997 Jul 9;236(1):54-8
9223425
Cancer Chemother Pharmacol. 2002 Oct;50(4):305-8
12357305